Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0OTQAU
ADC Name
hL49-HALC-PBD
Synonyms
hL49-HALC-PBD
   Click to Show/Hide
Organization
SEAGEN INC.
Drug Status
Investigative
Drug-to-Antibody Ratio
2
Antibody Name
hL49-HALC
  Antibody Info 
Antigen Name
Melanotransferrin (MELTF)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
Combination Type
PBD
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC69) 
12
nM
CVCL_0132
Amelanotic melanoma
Half Maximal inhibitory Concentration (lC64) 
5
nM
CVCL_1059
Melanoma
Half Maximal inhibitory Concentration (lC64) 
52
nM
CVCL_2075
Melanoma
Half Maximal inhibitory Concentration (lC62) 
68
nM
CVCL_2003
Cutaneous melanoma
Half Maximal inhibitory Concentration (lC55) 
14
nM
CVCL_0527
Cutaneous melanoma
Half Maximal inhibitory Concentration (lC50) 
32
nM
CVCL_0527
Cutaneous melanoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC69)
12 nM
Method Description
Tumor cells (A375) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Amelanotic melanoma A375 cells CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC64) 5 nM Moderate MELTF expression (MELTF++)
Method Description
Tumor cells (A2058) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Melanoma A2058 cells CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC64)
52 nM
Method Description
Tumor cells (IGR37) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Melanoma IGR37 cells CVCL_2075
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC62)
68 nM
Method Description
Tumor cells (Colo853) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Cutaneous melanoma Colo853 cells CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC55)
14 nM
Method Description
Tumor cells (SK-MEL-5) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Cutaneous melanoma SK-MEL-5 cells CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
32 nM
Method Description
Tumor cells (SK-MEL-28) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model Cutaneous melanoma SK-MEL-5 cells CVCL_0527
References
Ref 1 Anti-CD228 antibodies and antibody-drug conjugates